Drug
Gemzar (gemcitabine)
Gemzar (gemcitabine) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
terminated125%
unknown125%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
NCT01144455
completedphase_2
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
NCT00557492
terminatedphase_2
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
NCT00051584
unknownphase_3
Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer
NCT00842660
Clinical Trials (4)
Showing 4 of 4 trials
NCT01144455Phase 2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
NCT00557492Phase 2
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
NCT00051584Phase 2
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
NCT00842660Phase 3
Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4